Clinical Trials Sponsored by Synlab Services

Total 5347 results

IRCCS SYNLAB SDN

Recruiting

Defining, Evaluating, and Sharing Methodologies for Quality Control in Diagnostic Imaging

Subjects Undergoing Diagnostic Imaging Tests

Italy
IRCCS SYNLAB SDN

Completed

Big Data and Genomic Imaging for the Development of Biomarkers and Nanovector Drugs Innovative for Diagnosis and Therapy of Inflammatory Processes in Dementia (BigImAGING)

Neurodegenerative Diseases

Italy
IRCCS SYNLAB SDN

Recruiting

Multidisciplinary Approach to Breast Cancer Through the Study of Altered Transcriptomic and Immune Accompanied by the Identification of Extractable Markers From the Radiodiagnostic Bioimaging

Breast Cancer Patients

Italy
IRCCS SYNLAB SDN

Recruiting

Study of Brain Anatomo-functional Substrates Related to the Use of Human Tool by Means of Simultaneous Acquisition of Magnetic Resonance Imaging and Electroencephalogram

Patients With Frontal and Parietal Lobe Dysfunction

Italy
IRCCS SYNLAB SDN

Completed

Multihormonal Deficiencies and miRNA Profile in Chronic Heart Failure: Effects of Combined Hormonal Replacement Therapy

Patients With Ischemic or Idiopathic Dilated Cardiomyopathy

Italy
Synlab Holding Deutschland GmbH

Completed

COVAG - Covid-19 Antigen Study - the Diagnostic Efficacy of SARS-CoV-2 Rapid Detection Tests (COVAG)

COVID-19 | SARS-CoV2 Infection | SARS (Disease)

Germany
MGB Biopharma Limited
Hammersmith Medicines Research; Innovate UK; Cambridge Regulatory Services; Phases... and other collaborators

Completed

Safety, Blood Levels and Effects of MGB-BP-3

Healthy
IRCCS SYNLAB SDN
Fondazione Santobono Pausilipon

Recruiting

Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.

Acute Lymphoblastic Leukemia, Pediatric

Italy
IRCCS SYNLAB SDN
Santobono-Pausilipon Hospital

Recruiting

Unravelling the Role of KCTD Protein Family in the Clinical Management of Childhood Acute Lymphoblastic Leukemias

Childhood Acute Lymphoblastic Leukemia

Italy
IRCCS SYNLAB SDN
Federico II University

Recruiting

Potential Role of Sirtuins as Epigenetic Biomarkers of the Patient With Atherosclerosis or Calcific Aortic Stenosis

Atherosclerosis and Calcific Aortic Stenosis With and Without Diabetes

Italy
Biotest
Accovion GmbH; ICON plc; SYNLAB Analytics and Services Germany GmbH; Phoenix Clinical... and other collaborators

Completed

Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

Congenital Afibrinogenemia | Congenital Hypofibrinogenemia

Bulgaria, Egypt, Germany, Lebanon, Tunisia
Syndax Pharmaceuticals

Terminated

A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer

Breast Cancer

United States
Syndax Pharmaceuticals

Recruiting

Study of Radiolabeled Revumenib in Adults With Acute Leukemia

Acute Leukemia

United States
Syndax Pharmaceuticals

Available

Expanded Access Program for SNDX-5613

Relapsed/Refractory Acute Leukemia

United States
Syndax Pharmaceuticals

Active, not recruiting

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) (AGAVE-201)

Chronic Graft-versus-host-disease

Korea, Republic of, United States, Spain, Taiwan, France, Singapore, Belgium, Germany, Italy, Canada, Israel, Australia, United Kingdom, Greece, Poland, Portugal
Syndax Pharmaceuticals

Active, not recruiting

A Phase 1/2 Study to Evaluate SNDX- 6352 in Participants With Active cGVHD

Chronic Graft-versus-host-disease

United States
Syndax Pharmaceuticals

Completed

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

Carcinoma, Non-Small Cell Lung | Non-Small-Cell Lung Carcinoma

United States
Syndax Pharmaceuticals

Terminated

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

COVID | ARDS | Coronavirus | Cytokine Storm | Cytokine Release Syndrome

United States
Syndax Pharmaceuticals

Terminated

A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma (ENGAGE-501)

Hodgkin's Lymphoma

United States
Syndax Pharmaceuticals

Completed

A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects

Healthy Volunteers | Volunteers | Normal Volunteers | Human Volunteers

United States
Syndax Pharmaceuticals

Completed

A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects

Healthy Volunteer | Drug Interaction

United States
Syndax Pharmaceuticals

Withdrawn

Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer (ENCORE305)

Breast Cancer

United States
YSLab

Completed

Efficacy of Two Nasal Products for Decongestion and Mucus Fluidification (DEFI)

Rhinitis

France
Sunnybrook Health Sciences Centre
Peel Regional Paramedic Service; Toronto Paramedic Services; Halton Region Paramedic... and other collaborators

Completed

DOuble SEquential External Defibrillation for Refractory VF Pilot Study (DOSE-VF)

Ventricular Fibrillation

Canada
Syndax Pharmaceuticals

Recruiting

A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Acute Myeloid Leukemias

United States
Syndax Pharmaceuticals

Recruiting

Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

Colorectal Cancer | Solid Tumors

United States
Syndax Pharmaceuticals

Recruiting

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage | Mixed Phenotype Acute Leukemia | Mixed Lineage Acute Leukemia

United States, Israel, Spain, Australia, Netherlands, Germany, Canada, France, Italy, Lithuania
Syndax Pharmaceuticals

Completed

A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

Solid Tumor | Unresectable Malignant Neoplasm | Locally Advanced Malignant Neoplasm | Metastatic Tumor

United States
Syndax Pharmaceuticals

Active, not recruiting

A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Undifferentiated Leukemia | Relapsed/Refractory Leukemias | Mixed Phenotype Acute Leukemia

United States, Canada
Syndax Pharmaceuticals

Terminated

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

Non Small Cell Lung Cancer

United States
Syndax Pharmaceuticals

Completed

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

ER+ Breast Cancer

Ireland, United Kingdom
Syndax Pharmaceuticals

Completed

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer (ENCORE301)

Breast Cancer | ER+ Breast Cancer | Estrogen Receptor-Positive Breast Cancer | Breast Cancer, Estrogen Receptor-Positive

United States, Czechia, Canada, Hungary, Russian Federation
Syndax Pharmaceuticals

Completed

Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms, Glandular and Epithelial | Digestive System Neoplasms | Endocrine Gland Neoplasms | Breast Neoplasms | Breast Diseases | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Bronchial Neoplasms | Solid... and other conditions

United States
Syndax Pharmaceuticals

Completed

Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

Breast Cancer | Estrogen Receptor Positive Breast Cancer

United States
Syndax Pharmaceuticals

Completed

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer (ENCORE110)

Breast Cancer | Lung Cancer | Non Small Cell Lung Cancer (NSCLC) | Estrogen Receptor Breast Cancer

United States
Syndax Pharmaceuticals

Completed

Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat

Healthy Volunteers | Volunteers | Normal Volunteers | Human Volunteers

United States
Syndax Pharmaceuticals

Completed

A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function

Renal Impairment | Healthy Volunteer

United States
YSLab

Not yet recruiting

Safety and Effectiveness of an Auricular Spray

Excessive Ear Wax
Palak Shah
Abbott Medical Devices

Completed

Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices (DOAC LVAD)

Heart Failure

United States
Syndax Pharmaceuticals
DevPro Biopharma

Recruiting

Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

Australia
Scalab CNRS 9193

Unknown

Orthophonic and / or Proprioceptive Treatment of Developmental Dyslexia. (Pro-Pho-Dys)

Developmental Dyslexia

France
Sunnybrook Health Sciences Centre
London Health Sciences Centre; Toronto Paramedic Services; Halton Region Paramedic... and other collaborators

Completed

DOuble SEquential External Defibrillation for Refractory VF (DOSEVF)

Ventricular Fibrillation | Out-Of-Hospital Cardiac Arrest

Canada
Synta Pharmaceuticals Corp.

Terminated

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (Galaxy 2)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV | Non-Small-Cell Lung Adenocarcinoma

United States, France, Spain, Netherlands, Czech Republic, Serbia, Romania, Germany, Belgium, Italy, Hungary, United Kingdom, Canada, Poland, Bosnia and Herzegovina, Austria, Slovenia, Croatia, Russian Federation, Ukraine
Synta Pharmaceuticals Corp.

Terminated

Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer (GALAXY)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV

United States, Belgium, Bosnia and Herzegovina, Canada, Croatia, Czech Republic, Germany, Poland, Romania, Russian Federation, Serbia, Spain, United Kingdom
Synta Pharmaceuticals Corp.

Completed

A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) (CHIARA)

Non Small Cell Lung Cancer

United States, Canada
Synta Pharmaceuticals Corp.

Completed

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States
Synta Pharmaceuticals Corp.

Terminated

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Melanoma

United States, Spain, Canada, Australia, Germany, Puerto Rico, Romania, United Kingdom
Synta Pharmaceuticals Corp.

Completed

A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes

Active, Moderate to Severe Rheumatoid Arthritis

Netherlands
Synta Pharmaceuticals Corp.

Unknown

Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

Canada
Synta Pharmaceuticals Corp.

Suspended

A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors

Metastatic Solid Tumors

United States

Clinical Trials Sponsored by Synlab Services

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations